Carfilzomib: a rare cause of posterior reversible encephalopathy syndrome

Ann Hematol. 2016 Oct;95(11):1923-4. doi: 10.1007/s00277-016-2769-9. Epub 2016 Aug 1.

Authors

Nurit Katz-Agranov¹, Jennifer Padilla², Joanna Scoon³, Sujith V Cherian⁴

Affiliations

¹ Department of Internal Medicine, The University of Texas Houston, Health Science Center, Houston, TX, USA. Nurit.S.Katz@uth.tmc.edu.
² Department of Neurology, The University of Texas, Health Science Center, Houston, TX, USA.
³ Department of Internal Medicine, The University of Texas Houston, Health Science Center, Houston, TX, USA.
⁴ Department of Pulmonary Critical Care and Sleep Medicine, The University of Texas, Health Science Center, Houston, TX, USA.

PMID: 27477479
DOI: 10.1007/s00277-016-2769-9

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dexamethasone / administration & dosage
Drug Substitution
Female
Humans
Magnetic Resonance Imaging
Middle Aged
Multiple Myeloma / drug therapy
Oligopeptides / administration & dosage
Oligopeptides / adverse effects*
Posterior Leukoencephalopathy Syndrome / chemically induced*
Posterior Leukoencephalopathy Syndrome / diagnostic imaging
Proteasome Inhibitors / adverse effects*
Proteasome Inhibitors / therapeutic use
Seizures / chemically induced

Substances

Oligopeptides
Proteasome Inhibitors
carfilzomib
Dexamethasone